1 Correction to: Clinical Drug Investigation https://doi.org/10.1007/s40261-020-00929-z
The original version of this article unfortunately contained a mistake. The correct information is given below.
Abstract—Results, 1st sentence, which previously read:
We figured empagliflozin’s CNT to be $664,464 (95% CI $499,872–$1,097,280), $1,535,387 (95% CI $886,074–$3,210,501) for canagliflozin, and $2,693,145 (95% CI $1,639,563–$11,092,206) for dapagliflozin.
Should read:
We figured empagliflozin’s CNT to be $664,464 (95% CI $499,872–$1,097,280), $1,353,387 (95% CI $886,074–$3,210,501) for canagliflozin, and $2,693,145 (95% CI $1,639,563–$11,092,206) for dapagliflozin.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Arbel, R., Aboalhasan, E., Hammerman, A. et al. Correction to: Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis. Clin Drug Investig 40, 773 (2020). https://doi.org/10.1007/s40261-020-00932-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-020-00932-4